Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA will conduct an advisory committee early in 2012 to discuss how to assess the cardiovascular risk of weight-loss drugs, Orexigen revealed June 3 in announcing the firm will halt development in the U.S. of its obesity medication Contrave.